Kobayashi Keisuke, Shimizu Eiji, Hashimoto Kenji, Mitsumori Makoto, Koike Kaori, Okamura Naoe, Koizumi Hiroki, Ohgake Shintaro, Matsuzawa Daisuke, Zhang Lin, Nakazato Michiko, Iyo Masaomi
Department of Psychiatry (K2), Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):658-63. doi: 10.1016/j.pnpbp.2005.04.010.
Little is known about biological predictors of treatment response in panic disorder. Our previous studies show that the brain-derived neurotrophic factor (BDNF) may play a role in the pathophysiology of major depressive disorders and eating disorders. Assuming that BDNF may be implicated in the putative common etiologies of depression and anxiety, the authors examined serum BDNF levels of the patients with panic disorder, and its correlation with therapeutic response to group cognitive behavioral therapy (CBT). Group CBT (10 consecutive 1 h weekly sessions) was administered to the patients with panic disorder after consulting the panic outpatient special service. Before treatment, serum concentrations of BDNF and total cholesterol were measured. After treatment, we defined response to therapy as a 40% reduction from baseline on Panic Disorder Severity Scale (PDSS) score as described by [Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 283, 2529-2536]. There were 26 good responders and 16 poor responders. 31 age- and sex-matched healthy normal control subjects were also recruited in this study. The serum BDNF levels of the patients with poor response (25.9 ng/ml [S.D. 8.7]) were significantly lower than those of the patients with good response (33.7 ng/ml [S.D. 7.5]). However, there were no significant differences in both groups of the patients, compared to the normal controls (29.1 ng/ml [S.D. 7.1]). No significant differences of other variables including total cholesterol levels before treatment were detected between good responders and poor responders. These results suggested that BDNF might contribute to therapeutic response of panic disorder. A potential link between an increased risk of secondary depression and BDNF remains to be investigated in the future.
关于惊恐障碍治疗反应的生物学预测指标,人们所知甚少。我们之前的研究表明,脑源性神经营养因子(BDNF)可能在重度抑郁症和饮食失调的病理生理学中起作用。假设BDNF可能与抑郁症和焦虑症的假定共同病因有关,作者检测了惊恐障碍患者的血清BDNF水平,以及其与团体认知行为疗法(CBT)治疗反应的相关性。在咨询惊恐门诊特殊服务后,对惊恐障碍患者实施团体CBT(连续10周,每周1小时)。治疗前,测量血清BDNF和总胆固醇浓度。治疗后,按照[Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 283, 2529-2536]所述,我们将治疗反应定义为惊恐障碍严重程度量表(PDSS)评分较基线降低40%。有26例治疗反应良好者和16例治疗反应不佳者。本研究还招募了31名年龄和性别匹配的健康正常对照者。治疗反应不佳患者的血清BDNF水平(25.9 ng/ml [标准差8.7])显著低于治疗反应良好患者(33.7 ng/ml [标准差7.5])。然而,与正常对照者(29.1 ng/ml [标准差7.1])相比,两组患者均无显著差异。治疗反应良好者和治疗反应不佳者之间在包括治疗前总胆固醇水平在内的其他变量上未检测到显著差异。这些结果表明,BDNF可能有助于惊恐障碍的治疗反应。继发性抑郁症风险增加与BDNF之间的潜在联系仍有待未来研究。